 |
|
|
|
|
|
|
|
TRELSTAR is a type of prescription drug known as a LHRH agonist, used for the treatment of advanced prostate cancer.
Prostate cancer is the most common cancer in men in the U.S., excluding skin cancer and is the third
leading cause of death due to cancer in men.
Men with prostate cancer have the option of several types of treatment including: watchful waiting,
surgery, radiation therapy, cryotherapy, chemotherapy and hormonal treatment. The goal of hormone therapy
is to keep cancer cells from getting the male hormones they need to grow. As a LHRH agonist TRELSTAR works
to achieve this goal.
|
|
|
|
|
Indications and Usage
TRELSTAR® Depot and TRELSTAR®
LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR
Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy
or estrogen administration are either not indicated or unacceptable to the patient. |
|
|
|
Safety Information
|
|
The most commonly reported adverse events associated with the use of TRELSTAR®
Depot/TRELSTAR® LA included hot flushes (58.6%/73.0%), skeletal pain
(12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%),
and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or
may become pregnant as well as patients who are hypersensitive to triptorelin, other
LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock
and angioedema have been received since 1986 (global experience) . As with all LHRH
agonists, triptorelin causes an initial transient increase in testosterone levels.
Patients may experience the onset or exacerbation of symptoms during this period,
including bone pain, neuropathy, hematuria, spinal cord compression, or urethral
or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or
urinary tract obstruction should be closely observed. |
|
|
|
|
|
|
|
|
|
